Phase II/III

Type: Keyphrase
Name: Phase II/III
First reported Apr 17 2014 - Updated Apr 18 2014 - 3 reports

Quintiles Recognized as Industry Leader in Phase II/III Research for Second Year in a Row

Quintiles Recognized as Industry Leader in Phase II/III Research for Second Year in a Row ... [Published Noodls - Apr 17 2014]
Entities: Phase II/III, Quintiles
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Delivery Strength from Midsize CROs

There is no denying that large contract research organizations (CROs) are increasing their share of the outsourced drug developmentmarket. Preferred provider lists are dominated by the large CROs and it seems every week brings a new announcement of a ... [Published Applied Clinical Trials - Apr 14 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Sunesis Pharmaceuticals Inc announces presentation of positive results from ongoing MD Anderson-Sponsored trial of Vosaroxin in AML and High-Risk MDS

Sunesis Pharmaceuticals Inc:Presentation of results from ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia (AML) ... [Published Reuters - Apr 08 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

4SC: Creating A More Valuable Asset

Clarity on resminostat strategy4 SC AG (VSCG.F) has clarified and simplified its development strategy for resminostat in first-line liver cancer. Having previously considered an adaptive Phase II/III study, requiring a partner and/or significant investment ... [Published Investing.com - Apr 08 2014]
First reported Apr 06 2014 - Updated Apr 06 2014 - 1 reports

Three on LabCorp board of directors to retire

Three members of the LabCorp board of directors will retire when their terms expire in May, the company announced.Doctors Arthur H. Rubenstein and M. Keith Weikel will retire May 14, as will Wendy E. Lane, the company said.In a related announcement, D. ... [Published Burlington Times-News - Apr 06 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 2 reports

Sunesis Announces MD Anderson Sponsored Trial of Vosaroxin in AML and High-Risk MDS Poster to be Presented …

(GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. ( SNSS ) today announced that updated data from the ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with previously ... [Published Yahoo! Finance - Apr 02 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 3 reports

LabCorp Appoints D. Gary Gilliland To Board

BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced that Drs. Arthur H. Rubenstein and M. Keith Weikel will retire from the Board at the conclusion of their current term on May 14, 2014 ... [Published Citybizlist - Mar 31 2014]
Entities: Labcorp, Genetics, Oncology
First reported Mar 24 2014 - Updated Mar 25 2014 - 1 reports

Valneva Announces Continuation of the Phase II/III Clinical Trial for its Pseudomonas Aeruginosa Vaccine Candidate

Details Category: Vaccines Published on Monday, 24 March 2014 16:55 Hits: 39 Valneva and co-development partner decided to continue ongoing trial following data review of the interim analyses, further internal assessments and discussions with European ... [Published PipelineReview - Mar 24 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 1 reports

VALNEVA Reports Annual Results 2013: Company sees first year of merger as operational and human success

Valneva Reports Annual Results 2013:Company sees first year of merger as operational and human success+ Net loss was EUR 24.1m in FY 2013 in line with company expectation and mainly driven by EUR 21.4 million of R&D expenses+ Total revenues ... [Published TD Ameritrade - Mar 24 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 1 reports

VALNEVA Announces Continuation of the Phase II/III Clinical Trial for its Pseudomonas aeruginosa Vaccine Candidate

Valneva Announces Continuation of the Phase II/III Clinical Trial for its Pseudomonas Aeruginosa Vaccine Candidate+ Valneva and co-development partner decided to continue ongoing trial following data review of the interim analyses, further internal assessments ... [Published Individual.com - Mar 24 2014]
First reported Mar 20 2014 - Updated Mar 20 2014 - 1 reports

Why Seek Access to Investigational Drugs?

Many people in America and around the world seek relief from chronic illness. Medications currently available and approved by the FDA may not help certain patients. The medical research community is constantly evaluating investigational medications; with ... [Published ABC 4 - Mar 20 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

DCRI Receives Top Customer Loyalty Scores in ISR's 6th Annual CRO Quality Benchmarking Study

SOURCE: Industry Standard ResearchCARY, NC--(Marketwired - Mar 19, 2014) - Industry Standard Research (ISR) is announcing the launch of its 6th annual CRO Quality Benchmarking series with today's release of its " CRO Quality Benchmarking - Phase II/III ... [Published MarketWired - Mar 19 2014]

Quotes

...The poster (Poster #7, Hall A-E, Poster Section 38) is titled "Phase I II study of vosaroxin and decitabine in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)." br Help employers find you! Check out all the jobs and post your resume
...said Farhad Ravandi, M D , Professor of Medicine, Department of Leukemia, University of Texas MD Anderson Cancer Center, and a study investigator. "Emerging outcomes from this trial suggest that vosaroxin and decitabine hold meaningful promise as a potential new combination treatment option for this population. The high number of complete remissions with good tolerability are highly encouraging and make this trial a designated priority for our center."
...members and have made tremendous contributions to LabCorp during their years of service," said David P King , Chairman and Chief Executive Officer. "Each has served with distinction, both as a Board member and as Chair of an important Board Committee. On behalf of the Board and LabCorp , I wish to express our gratitude for their invaluable leadership and years of dedicated service to the Company. At the same time we are committed to Board renewal and succession planning, and these changes reflect that ongoing process."
..."This is another significant moment for our Company as we bring our third compound into clinical trials," commented Leo Ehrlich, CEO at Cellceutix. "A steady stream of developments has led to a great start to 2014 for our Company. We initiated a multi-center Phase IIb trial of our novel antibiotic Brilacidin. The Phase IPhase I trial of our novel anticancer compound Kevetrin is in the seventh cohort and now Prurisol is set to enter human trials, positioning us with three clinical drug candidates targeting three different areas of unmet medical need."

More Content

All (69) | News (59) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (5)
sort by: Date | Relevance
Quintiles Recognized as Industry Leader in Phas... [Published Noodls - Apr 17 2014]
Quintiles Recognized as Industry Leader in Phas... [Published Business Wire Health News - Apr 17 2014]
Quintiles Recognized as Industry Leader in Phas... [Published Quintiles Transnational - Apr 17 2014]
Delivery Strength from Midsize CROs [Published Applied Clinical Trials - Apr 14 2014]
Sunesis Pharmaceuticals, Inc. Announces Present... [Published BioSpace - Apr 08 2014]
The Royal Marsden is committed to promoting the... [Published Private Healthcare UK - Apr 08 2014]
Sunesis Pharmaceuticals Inc announces presentat... [Published Reuters - Apr 08 2014]
Sunesis Announces Presentation of Positive Resu... [Published Virtual Strategy Magazine - Apr 08 2014]
4SC: Creating A More Valuable Asset [Published Investing.com - Apr 08 2014]
Sunesis Announces Presentation of Positive Resu... [Published Benzinga.com - Apr 08 2014]
Three on LabCorp board of directors to retire [Published Burlington Times-News - Apr 06 2014]
Aptiv Solutions Enables First Surrogate Endpoin... [Published Samedan Ltd Pharmaceutical Publishers - Apr 04 2014]
LABORATORY OF AMERICA : LabCorp Reports Changes... [Published 4 Traders - Apr 03 2014]
Sunesis Announces MD Anderson Sponsored Trial o... [Published Yahoo! Finance - Apr 02 2014]
Sunesis Announces MD Anderson Sponsored Trial o... [Published Benzinga.com - Apr 02 2014]
Pink Sheet - Colon Cancer Community Weighs “Mas... [Published Friends of Cancer Research - Mar 31 2014]
LabCorp Appoints D. Gary Gilliland To Board [Published Citybizlist - Mar 31 2014]
LabCorp Announces Changes To Board; Appoints Ga... [Published RTTNews.com - Mar 31 2014]
LabCorp Announces Changes to Board of Directors [Published Enhanced Online News - Mar 31 2014]
Cellceutix to commence psoriasis trial [Published Individual.com - Mar 31 2014]
Stellar Biotechnologies: Low Risk Biotech Provi... [Published Seeking Alpha - Mar 29 2014]
Recent Advances in the Treatment of SLE [Published General Medicine eJournal - Mar 26 2014]
Can-Fite to Present at the 9th International Co... [Published Nasdaq - Mar 25 2014]
Valneva Announces Continuation of the Phase II/... [Published PipelineReview - Mar 24 2014]
VALNEVA Reports Annual Results 2013: Company se... [Published TD Ameritrade - Mar 24 2014]
VALNEVA Announces Continuation of the Phase II/... [Published Individual.com - Mar 24 2014]
Kamada defers trial results release [Published Globes - Mar 23 2014]
EDAP TMS : Completes FDA Q&A Session for Its Ab... [Published 4 Traders - Mar 20 2014]
Why Seek Access to Investigational Drugs? [Published ABC 4 - Mar 20 2014]
Astellas, Daiichi Sankyo to Share Compound Libr... [Published FDA News - Mar 19 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Quintiles Recognized as Industry Leader in Phas... [Published Business Wire Health News - Apr 17 2014]
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Quintiles recognized for its service quality in Phase ll/lll research by Industry Standard Research. ...
Torii Pharmaceutical reports positive trial res... [Published PBR - News - Mar 10 2014]
ALK has announced that its partner for Japan, Torii Pharmaceutical, has reported positive results from its Phase II/III trial into ALK's sublingual allergy immunotherapy tablet (SLIT-tablet) for house dust mite-induced allergic rhinitis (hay fever). ...
1

Press Releases

sort by: Date | Relevance
ALK’s partner for Japan reports positive trial ... [Published GlobeNewswire: Advertising News - Mar 10 2014]
CRO Quality Benchmarking - Phase II/III Service... [Published Financial Services - Jan 31 2014]
Tauriga Sciences Inc. Receives Positive Update ... [Published GlobeNewswire: Acquisitions News - Jan 03 2014]
DGAP-Adhoc: PAION AG REPORTS HEADLINE DATA OF O... [Published GlobeNewswire: Acquisitions News - Nov 14 2013]
DGAP-News: PAION AG REPORTS HEADLINE DATA OF ON... [Published GlobeNewswire: Acquisitions News - Nov 14 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.